Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis
Por:
Diels, J, Thilakarathne, P, Cameron, C, McElligott, S, Schubert, A, Puig, L
Publicada:
1 ago 2020
Ahead of Print:
1 ene 2020
Resumen:
Background Guselkumab is an interleukin-23 inhibitor indicated for the treatment of moderate-to-severe plaque psoriasis in adults. Guselkumab has demonstrated additional benefit in patients with early inadequate response to ustekinumab. Long-term efficacy comparisons of guselkumab and ustekinumab are currently lacking among ustekinumab-naive patients. Objectives To assess the relative efficacy of guselkumab and ustekinumab for maintenance therapy of moderate-to-severe plaque psoriasis, using individual patient data (IPD) from randomized controlled trials. Methods IPD for guselkumab from the VOYAGE 1 and 2 trials were pooled and compared with IPD for ustekinumab from the NAVIGATE trial. Multivariable logistic regression analyses compared guselkumab 100 mg and ustekinumab 45 mg or 90 mg for the achievement and maintenance of Psoriasis Area and Severity Index (PASI) 90, 75 and 100 responses up to 40 weeks. The regression models accounted for a range of clinically relevant covariates (e.g. age, sex, psoriasis duration). Relative efficacy was expressed using odds ratios (ORs) and predicted probability of treatment response associated with each intervention. Results Patients receiving guselkumab had significantly higher probabilities of achieving a PASI 90 response than patients receiving ustekinumab, at both week 16 [70 center dot 4% vs. 46 center dot 0%, OR 2 center dot 79, 95% confidence interval (CI) 2 center dot 22-3 center dot 45] and week 40 (74 center dot 2% vs. 54 center dot 5%, OR 2 center dot 40, 95% CI 1 center dot 89-3 center dot 13]. Guselkumab was also associated with a significantly increased likelihood of achieving both PASI 75 and PASI 100 responses at weeks 16 and 40, compared with ustekinumab. Conclusions Adjusted analyses leveraging IPD demonstrate that guselkumab has a significantly higher probability of achieving and maintaining PASI treatment responses through week 40 than ustekinumab does.
Filiaciones:
Diels, J:
Janssen Res & Dev LLC, Raritan, NJ 08869 USA
Thilakarathne, P:
Janssen Res & Dev LLC, Raritan, NJ 08869 USA
Cameron, C:
Comerstone Res Grp Inc, Evidence Synth, Burlington, ON, Canada
McElligott, S:
Janssen Res & Dev LLC, Raritan, NJ 08869 USA
Schubert, A:
Janssen Cilag Polska, Warsaw, Poland
Puig, L:
Hosp Santa Creu & Sant Pau, Dermatol, Barcelona, Spain
Hybrid Gold, Green Published
|